Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01428297 | A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome | PHASE1 | COMPLETED | 12 | — | — | May 1, 2011 | Feb 1, 2014 | Dec 8, 2020 | 4 | United States, Netherlands |
| Arm | Type | Description |
|---|---|---|
| Cohort A and B, BPR277 and Placebo (vehicle) | EXPERIMENTAL | - |
| Part 2 BPR277 | EXPERIMENTAL | - |
| Part 2 Placebo (vehicle) | PLACEBO_COMPARATOR | - |
| Part 3 BPR277 and Placebo (vehicle) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BPR277 ointment (controlled application) | DRUG | - |
| Placebo (Vehicle) | DRUG | - |
| BPR277 ointment | DRUG | - |
| BPR277 | DRUG | - |
Inclusion Criteria: Part 1 Healthy volunteers * Healthy male and female subjects of non childbearing potential, 18 to 65 years of age inclusive and in good health Part 2 Patients with atopic dermatitis: * Male and female subjects, 18 to 65 years of age inclusive and having passed screening exami...